Pharmaceutical giant Galderma has released new clinical data indicating that the specific sequence in which injectable aesthetic treatments are administered can significantly influence skin-quality outcomes in menopausal women. The findings, derived from an extensive eight-month, investigator-initiated trial led by prominent plastic surgeon Mr. Andreas Nikolis and supported by Galderma, shed new light on the biological responses of aging skin to combination therapies. By evaluating the interplay between hyaluronic acid skin boosters and poly-L-lactic acid collagen stimulators, the research challenges traditional one-size-fits-all approaches to aesthetic medicine and highlights the critical need for tailored treatment protocols for patients navigating hormonal transitions.
The clinical investigation specifically evaluated two distinct treatment sequences applied to the face and décolletage. Participants were divided into protocols that administered a hyaluronic acid skin booster, specifically Restylane Skinboosters, prior to a poly-L-lactic acid collagen stimulator, known commercially as Sculptra. Alternatively, the control cohorts received the reverse sequence, initiating therapy with the collagen stimulator before the application of the skin booster. Over the course of the eight-month observation window, researchers tracked cellular changes, dermal architecture, and patient-reported outcomes to determine whether sequencing played a measurable role in long-term aesthetic and physiological efficacy.
According to the study findings, the protocol that prioritized the hyaluronic acid skin booster first produced a notably earlier visible response alongside superior dermal remodelling. Clinical metrics revealed that facial dermal thickness increased by an impressive 27.3 percent among participants who received the skin booster followed by the collagen stimulator. In contrast, the cohort receiving the collagen stimulator first experienced a more modest dermal thickness increase of 15.7 percent. While both treatment sequences successfully improved overall skin hydration and generated high levels of patient-reported satisfaction, the quantitative divergence in dermal restructuring underscores the importance of foundational hydration before targeted collagen biostimulation in menopausal skin.
Background Context of the Menopausal Skin Shift
To fully understand the significance of Galderma’s findings, it is necessary to examine the physiological transformations that occur within the integumentary system during menopause. The drop in estrogen levels associated with menopause triggers a rapid decline in collagen production, leading to an estimated loss of up to 30 percent of dermal collagen within the first five years following the onset of menopause. This drastic reduction is accompanied by decreased lipid production, impaired barrier function, and a significant loss of dermal hyaluronic acid, which naturally binds moisture within the skin matrix.
Consequently, menopausal skin frequently exhibits accelerated dryness, thinning, loss of elasticity, and increased fragility. Traditional aesthetic interventions have often treated these symptoms with generalized anti-aging protocols designed for younger cohorts or photo-damaged skin rather than hormonally altered tissue. Aesthetic practitioners have increasingly recognized that standard multi-modal therapies—combining hydrating agents with biostimulatory products—are necessary to address these multifaceted deficits. However, until now, clinical data regarding the optimal chronology of administering these complementary substances remained largely unexplored, leaving clinicians to rely on empirical observation rather than empirical science.
Chronology of the Research Initiative and Global Survey
The eight-month trial represents the culmination of a broader, multi-phase research initiative spearheaded by Galderma to bridge the knowledge gap surrounding menopausal skin health. The investigation began with a foundational phase involving qualitative and quantitative assessments of skin physiology under hormonal decline, culminating in the design of Mr. Nikolis’s clinical protocol.
Running parallel to the clinical trial, Galderma commissioned a massive international survey encompassing 5,090 women across the United Kingdom, the United States, Brazil, and China. This survey was designed to capture consumer awareness, treatment behaviors, and psychological impacts associated with menopausal skin changes. The survey results revealed a profound disconnect between the aesthetic needs of menopausal women and the availability of targeted, science-backed educational resources. The combination of the multi-country consumer survey and the rigorous eight-month clinical trial provided researchers with a comprehensive dataset, bridging microscopic cellular measurements with macroscopic patient experiences across diverse global populations.
Official Responses and Industry Reactions
The release of these clinical insights has drawn substantial attention from industry leaders, dermatologists, and aesthetic practitioners worldwide. Commenting on the findings, Anne-Cécile Chevrier, global head for injectable aesthetics at Galderma, emphasized the broader implications of the research for the aesthetic medicine sector.
"Our research shows the scale of this knowledge gap and the need to move beyond a one-size-fits-all ageing narrative," stated Chevrier. "At Galderma, we are committed to advancing the understanding of menopausal skin and providing women with clear, trusted information and science-backed solutions, so they can make informed choices and feel confident in their skin throughout this important stage of life."
Independent dermatological experts not directly affiliated with the trial have also weighed in on the data. Many clinical practitioners have noted that the findings provide a rational framework for sequencing treatments that were previously combined based solely on practitioner preference. By demonstrating that hyaluronic acid primes the extracellular matrix to better receive subsequent biostimulatory treatments, the study offers a biological mechanism that explains the enhanced dermal thickness observed in the skin-booster-first cohort.
Broader Impact and Clinical Implications for Aesthetic Medicine
The implications of Galderma’s research extend far beyond the specific products evaluated in the trial, pointing toward a more sophisticated era of personalized aesthetic medicine. As the global population ages and a growing demographic of women approach and navigate menopause with higher expectations for vitality and appearance, the demand for evidence-based treatments tailored to hormonal life stages is surging.
For aesthetic practitioners, the study mandates a shift in treatment planning. Rather than administering injectables concurrently or in arbitrary sequences, clinicians may now utilize these findings to optimize patient outcomes by sequencing hydration-focused treatments ahead of collagen-stimulating interventions. This sequential approach maximizes the receptivity of the dermal tissue, potentially reducing the total number of sessions required to achieve desired structural improvements while enhancing long-term skin health.
Furthermore, the integration of extensive global survey data with hard clinical metrics sets a new benchmark for corporate research in the aesthetics industry. By addressing not only the physical manifestations of hormonal aging but also the psychological confidence of the patient, Galderma’s initiative signals a cultural shift in how beauty and wellness brands approach the menopausal transition. As ongoing research continues to uncover the intricate relationships between hormones, skin biology, and aesthetic interventions, patients can anticipate more predictable, efficacious, and personalized care pathways designed to support their skin health across every stage of life.
